gemfibrozil
Selected indexed studies
- Gemfibrozil. (IARC Monogr Eval Carcinog Risks Hum, 1996) [PMID:9097130]
- Gemfibrozil-induced myopathy. (Arch Intern Med, 1991) [PMID:1888257]
- Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. (Expert Opin Drug Metab Toxicol, 2017) [PMID:27548563]
_Worker-drafted node — pending editorial review._
Connections
gemfibrozil is a side effect of
Sources
- Gemfibrozil. (1996) pubmed
- Gemfibrozil-induced myopathy. (1991) pubmed
- Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. (2017) pubmed
- Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. (1996) pubmed
- Gemfibrozil in Combination with Statins-Is It Really Contraindicated? (2016) pubmed
- Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. (1988) pubmed
- Gemfibrozil-induced impotence. (1990) pubmed
- [Gemfibrozil-induced myopathy]. (1993) pubmed
- Gemfibrozil-Induced Intracellular Triglyceride Increase in SH-SY5Y, HEK and Calu-3 Cells. (2023) pubmed
- Gemfibrozil, stretching arms beyond lipid lowering. (2009) pubmed